Dumont & Blake Investment Advisors Increased Its Metlife (MET) Position; THERATECHNOLOGIES (THERF) Shorts Decreased By 7.14%

April 25, 2018 - By David Stenberg

MetLife, Inc. (NYSE:MET) Logo

THERATECHNOLOGIES INC (OTCMKTS:THERF) had a decrease of 7.14% in short interest. THERF’s SI was 425,600 shares in April as released by FINRA. Its down 7.14% from 458,300 shares previously. With 74,100 avg volume, 6 days are for THERATECHNOLOGIES INC (OTCMKTS:THERF)’s short sellers to cover THERF’s short positions. The SI to THERATECHNOLOGIES INC’s float is 0.58%. The stock decreased 0.95% or $0.07 during the last trading session, reaching $7.19. About 47,349 shares traded. Theratechnologies Inc. (OTCMKTS:THERF) has 0.00% since April 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Dumont & Blake Investment Advisors Llc increased Metlife Inc (MET) stake by 1008.56% reported in 2017Q4 SEC filing. Dumont & Blake Investment Advisors Llc acquired 39,334 shares as Metlife Inc (MET)’s stock declined 10.38%. The Dumont & Blake Investment Advisors Llc holds 43,234 shares with $2.19M value, up from 3,900 last quarter. Metlife Inc now has $49.58 billion valuation. The stock increased 0.46% or $0.22 during the last trading session, reaching $47.83. About 4.89 million shares traded. MetLife, Inc. (NYSE:MET) has declined 1.24% since April 25, 2017 and is downtrending. It has underperformed by 12.79% the S&P500.

Among 19 analysts covering MetLife (NYSE:MET), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. MetLife had 56 analyst reports since July 31, 2015 according to SRatingsIntel. Sandler O’Neill maintained MetLife, Inc. (NYSE:MET) on Thursday, April 5 with “Hold” rating. The stock of MetLife, Inc. (NYSE:MET) earned “Outperform” rating by FBR Capital on Monday, August 29. Standpoint Research downgraded the stock to “Hold” rating in Friday, December 9 report. The firm has “Overweight” rating given on Friday, August 11 by Barclays Capital. The company was initiated on Thursday, January 26 by Citigroup. The firm has “Buy” rating by Wells Fargo given on Wednesday, April 19. The firm has “Buy” rating given on Friday, November 3 by RBC Capital Markets. The rating was initiated by Bank of America on Monday, March 26 with “Hold”. The stock of MetLife, Inc. (NYSE:MET) earned “Hold” rating by Sandler O’Neill on Thursday, February 15. The firm has “Buy” rating given on Wednesday, June 28 by Wells Fargo.

Investors sentiment increased to 1.02 in Q4 2017. Its up 0.13, from 0.89 in 2017Q3. It improved, as 45 investors sold MET shares while 330 reduced holdings. 93 funds opened positions while 290 raised stakes. 782.94 million shares or 0.24% less from 784.85 million shares in 2017Q3 were reported. Moreover, Financial Engines Advsrs Ltd has 0% invested in MetLife, Inc. (NYSE:MET). The Florida-based Dreman Value L L C has invested 0.88% in MetLife, Inc. (NYSE:MET). Windward Mngmt Ca reported 126,540 shares stake. Diamond Hill Mgmt Inc reported 7.86 million shares. Riverpoint Cap Management Limited Liability Co has invested 1.12% in MetLife, Inc. (NYSE:MET). Loeb Corp reported 0.73% stake. Federated Investors Pa accumulated 0.01% or 43,708 shares. Kcm Inv Limited Liability Corp has 4,214 shares for 0.01% of their portfolio. Franklin Street Inc Nc holds 1.16% of its portfolio in MetLife, Inc. (NYSE:MET) for 153,841 shares. Exxonmobil Invest Mngmt Inc Tx has 167,320 shares for 0.23% of their portfolio. Schwerin Boyle Cap invested in 120,380 shares. Wealthcare Cap Management Ltd Liability Co invested 0% of its portfolio in MetLife, Inc. (NYSE:MET). First Republic Invest Incorporated invested 0.03% in MetLife, Inc. (NYSE:MET). Exane Derivatives holds 1,263 shares. Keybank National Association Oh has invested 0.14% in MetLife, Inc. (NYSE:MET).

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. The company has market cap of $542.55 million. The Company’s lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. It currently has negative earnings.

MetLife, Inc. (NYSE:MET) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: